Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II neoadjuvant cetuximab + oxaliplatin + 5-FU with concurrent radiation in locally advanced oesophageal squamous cell carcinoma
2006-001097-24Phase 2Completed
- Sponsor
- Technical University of Munich
- Start
- May 2006
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, oxaliplatin and fluorouracil in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Technical University of Munich. Primary endpoint: Maximal tolerated dose of cetuximab + oxaliplatin with concurrent radiation (Phase I). Started May 2006; status: completed.
02
Drugs
cetuximaboxaliplatinfluorouracil
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2006-001097-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001097-24.